Jan 20 2010
- Key Trial for Oral Insulin With Expected Results at the End of Q1 of
2010
Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) announced today the
completion of patient enrollment in the Phase 2B clinical study of its oral
insulin capsule, ORMD-0801. The last of the thirty Type II diabetes patients
was enrolled for a study in which subjects will be administered the
insulin-based capsule for a period of six weeks.
The randomized, double-blind, placebo-controlled, multi-centered study
will evaluate the safety, tolerability, and efficacy of Oramed's oral insulin
delivery technology. The study is taking place in five locations throughout
South Africa and is being monitored by OnQ Consulting, a clinical research
organization (CRO) based in Johannesburg, South Africa. Study results are
expected by the end of first quarter of 2010.
This trial marks an important milestone in ORMD-0801 safety testing,
assessing the first indication of ORMD-0801 on a large group of volunteers
over an extended treatment period.
"The closing of enrollment for the Phase 2B trial is an exciting
accomplishment for us, as it moves us closer to completing this trial and
receiving the results. In the upcoming months, we look forward to being able
to share the results from the trial, which will mark a major milestone in the
development of oral insulin," explained Nadav Kidron, CEO of Oramed
Pharmaceuticals.
SOURCE Oramed Pharmaceuticals Inc.